The Expression Of VEGF, Nuclear EGFR And CD105in Early Stage Non-small Cell Lung Cancer And Their Clinical Significance

Objective:To detect the expression of vascular endothelial growth factor(VEGF), nuclear epidermal growth factor receptor(EGFR) and CD105in the early non-small cell lung cancer, then analyze the relationship of these indices with the clinicopathologic features of early stage NSCLC and the correlation with each other. Methods:The expression status of VEGF, nuclear EGFR and CD105were examined by immunohistochemistric method (IHC) in30cases of early-stage non-small cell lung cancer and adjacent normal tissue. Measurement data between groups were compared using t test, count data using the chi-square test or exact fourfold table test, the correlation between the non-parametric Spearman rank correlation analysis. Results:The positive rates of VEGF of30patients with early stage non-small cell lung cancer and adjacent normal tissue was53.5%and26.7%, respectively, the difference was statistically significant (P=0.021). The positive rates of nuclear EGFR of30patients with early stage non-small cell lung cancer and adjacent normal tissue was16.7%and0%, respectively, the difference was no statistically significant (P>0.05). MVD marked by CD105of30patients with early stage non-small cell lung cancer and adjacent normal tissue were17.3±5.6and8.9±4.2in the adjacent tissues and normal tissues, the difference was statistically significant (P=0.000). The expression of VEGF and nuclear EGFR were significantly correlated with tumor recurrence and metastasis (P=0.045;0.010), The expression of VEGF and nucleus EGFR, as well as the expression of nucleus EGFR and MVD were no significant correlation (P>0.05).Conclusion:VEGF, nucleus EGFR and CD105plays an important role in the development of early-stage non-small cell lung cancer recurrence VEGF, EGFR expression in the nucleus of early non-small cell lung cancer metastasis.